Ex Vivo Gene-editing Platforms for T Cells

The U CAR-T platform aims to develop innovative therapies for cancer patients.

It aims to remove the immunological rejection molecules on the T cells of a healthy donor through gene editing, and transform such molecules via CAR to prepare off-the-shelf allogeneic CAR-T to treat patients.

Advantages of the Platform

- Off the shelf

- Better quality product from a healthy donor

- More effective quality control

- Uniformity of products

- Flexible clinical application

- Low costs

In February 2022, EdiGene announced a non-exclusive, worldwide license agreement with Arbor Biotechnologies to access Arbor’s proprietary CRISPR gene editing technology for certain ex vivo engineered cell therapy programs in the field of oncology.